about
Protein tyrosine phosphatase PRL-3 in malignant cells and endothelial cells: expression and functionIntegrating Colon Cancer Microarray Data: Associating Locus-Specific Methylation Groups to Gene Expression-Based Classifications.Patient-derived xenograft models: an emerging platform for translational cancer researchInterrogation of gossypol therapy in glioblastoma implementing cell line and patient-derived tumour models.Comparison of performance in a four year graduate entry medical programme and a traditional five/six year programme.Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.The hydroxylase inhibitor dimethyloxallyl glycine attenuates endotoxic shock via alternative activation of macrophages and IL-10 production by B1 cells.Validation of an imageable surgical resection animal model of Glioblastoma (GBM).AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapantGuanine nucleotide exchange factor Dock7 mediates HGF-induced glioblastoma cell invasion via Rac activation.Bioluminescent imaging: a critical tool in pre-clinical oncology research.Recent advances in molecular imaging biomarkers in cancer: application of bench to bedside technologies.The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.Molecular imaging in the development of a novel treatment paradigm for glioblastoma (GBM): an integrated multidisciplinary commentary.Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approach.Mechanistic interrogation of combination bevacizumab/dual PI3K/mTOR inhibitor response in glioblastoma implementing novel MR and PET imaging biomarkers.Modelling tumour cell proliferation from vascular structure using tissue decomposition into avascular elements.The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?The chain length of biologically produced (R)-3-hydroxyalkanoic acid affects biological activity and structure of anti-cancer peptides.Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors.Interrogating open issues in cancer precision medicine with patient-derived xenografts.The anti-cancer activity of a cationic anti-microbial peptide derived from monomers of polyhydroxyalkanoate.Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.Knockdown of human deubiquitinase PSMD14 induces cell cycle arrest and senescence.Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer.Supramolecular photonic therapeutic agents.Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer.Erythrophagocytosis by angiogenic endothelial cells is enhanced by loss of erythrocyte deformability.Regulation of apoptosis in the bovine blastocyst by insulin and the insulin-like growth factor (IGF) superfamily.PDX-MI: Minimal Information for Patient-Derived Tumor Xenograft Models.In vivo bioluminescence imaging validation of a human biopsy-derived orthotopic mouse model of glioblastoma multiforme.Comparison of anthropometric-based equations for estimation of body fat percentage in a normal-weight and overweight female cohort: validation via air-displacement plethysmography.Analysis of apoptosis in the preimplantation bovine embryo using TUNEL.Interrogating open issues in cancer medicine with patient-derived xenografts.An intact canonical NF-κB pathway is required for inflammatory gene expression in response to hypoxia.Interrogation of transcriptomic changes associated with drug-induced hepatic sinusoidal dilatation in colorectal cancer.Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
P50
Q28299442-FCF811B0-8D80-41FA-BCBD-676F130BA6F3Q31127007-AE123E0A-327B-4BEE-8DDB-64085EBA67A3Q34205518-C7F18288-9DDC-4F0F-A6F4-E760B45CE9A0Q34687012-41356CB8-93EE-479D-B37E-BBBDEBC36FC6Q34712610-9C835A43-27C7-44DF-AA4B-8833BA96CDFAQ35007826-08E6EC28-FBF5-40B3-B774-CF246E6E7BD8Q35167567-7DE711F5-3350-4155-9DD9-B2D80EC0FFF3Q35192671-9E49D6BA-A596-4411-8FF9-FD69C46643D5Q36101969-0BF3BDCE-5854-4949-85EE-D42E564265B4Q36262416-B59FCE51-382C-4636-B792-780A2F623AD6Q36750717-5EBF4ACA-308B-478A-84D1-25BDF98D5C00Q37632169-9EBC0D45-98EC-489B-845D-B3A48FEADEF9Q37646517-A35260F3-F3D2-4937-B0FE-321659B6C9D4Q37662855-89F0D509-65BC-41C2-8182-798B5E94AA4EQ37832021-DC5AFD5B-536D-4CB2-9883-B591C5566E03Q38116304-64B7C749-2DB0-454F-B0D7-D0C91FF021D2Q38373884-DB8123DA-EA2F-4212-984F-22E9A5746ACDQ38786526-3278DA95-D3E2-4205-B3A6-1BDAB5A53C4FQ38870352-F5BD1F91-A836-45DA-A21E-FD86F14CC4ECQ38879975-8D8DC656-CF49-4831-A79D-312BB40C926CQ38893598-D563D1B2-0EC2-42C6-971B-8423E96881FDQ38990224-67C65819-C0C5-4977-A285-5A724A9C1F41Q39095733-52E42095-2DDF-4B26-A5DC-01D3011649DEQ39205999-E7896C38-2267-47F5-B240-A63C3BEFA84AQ39727725-4EBDB543-26D8-4E52-9A62-66C3EC0F67D5Q39803335-A7DC48D7-CD2F-40B4-A87F-1263773C8840Q39903262-0C32B3C5-9F30-4E51-A4FB-CC338EC72CFAQ40348307-089594E7-4FA1-4312-AD9F-B5E09157DB38Q40534552-27207D24-5C77-4D4F-9827-345F25FECB4DQ41892380-60392B3D-5BAB-42D2-A1CA-F3E5A9941FA0Q43166153-6114BDD0-8EB4-43E3-99D9-FB59BF276475Q44060548-53D70315-51B5-4635-8BBE-42F6E8EB8637Q45961634-B77ABE08-866F-434C-A832-92D604A9E05CQ46567427-EAE1C347-C427-410B-81D9-AF08E1DBF04BQ47175434-332B7C46-042B-449F-9649-512E593D4659Q48900782-6197407B-6BBC-401E-BE50-C82BE005BD2BQ50080940-EC4C1844-FC60-42EA-A894-93A97B94CA4AQ52605903-D7DD7FFA-6DA4-4FEC-9C93-878545D23486Q55271038-8F8F96B8-4BBE-4AEF-84B9-A2051687099EQ57022679-EF640458-05AA-4C95-842E-2BA8A65539E1
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Annette T. Byrne
@ast
Annette T. Byrne
@en
Annette T. Byrne
@es
Annette T. Byrne
@nl
Annette T. Byrne
@sl
type
label
Annette T. Byrne
@ast
Annette T. Byrne
@en
Annette T. Byrne
@es
Annette T. Byrne
@nl
Annette T. Byrne
@sl
prefLabel
Annette T. Byrne
@ast
Annette T. Byrne
@en
Annette T. Byrne
@es
Annette T. Byrne
@nl
Annette T. Byrne
@sl
P106
P1153
9736329300
P21
P31
P496
0000-0003-0287-8899